Can-Fite BioPharma: Enrollment ongoing in study of Namodenoson in liver cancer

“A patient who had participated in Can-Fite’s prior Phase II liver cancer study who continues to receive treatment with Namodenoson under a compassionate use program now has overall survival of 6.9 years with the disappearance of ascites, normal liver function, and good quality of life, defined as a complete response. Enrollment is ongoing in Can-Fite’s pivotal Phase III study of Namodenoson in the treatment of advanced liver cancer. During the third quarter, the American Society of Clinical Oncology ASCO selected Can-Fite for the prestigious Breakthrough Abstract Award from Conquer Cancer for its abstract titled “A novel approach for the treatment of advanced hepatocellular carcinoma HCC “.